Advertisement

Topics

Amryt Pharma to tweak protocol for its epidermolysis bullosa phase III study

04:30 EDT 17 Apr 2018 | Proactive Investors

The dramatic increase in revenues in 2017 to €12.8mln reflected a full year's contribution from sales of Lojuxta, which is used to treat the rare, life-threatening cholesterol disorder, HoFH.

Original Article: Amryt Pharma to tweak protocol for its epidermolysis bullosa phase III study

NEXT ARTICLE

More From BioPortfolio on "Amryt Pharma to tweak protocol for its epidermolysis bullosa phase III study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cholesterol
Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...